Temple University cherry "T" logo

Lewis Katz School of Medicine

Search Keywords

Oscar A Marcos-Contreras, PharmD, PhD

Oscar A Marcos-Contreras, PharmD, PhD

Oscar A Marcos-Contreras, PharmD, PhD

  • Lewis Katz School of Medicine

    • Pathology and Laboratory Medicine

      • Assistant Professor

RESEARCH INTERESTS

  • Stroke, neuroinflammatory diseases, multiple sclerosis, TBI, AD
  • Acute and chronic neurological disases.
  • Blood-brain barriers
  • Stroke.
  • Nanomedicine.
  • Gene therapy.
  • Hematology.

EDUCATION

  • PharmD. University of Alcalá 2004.
  • PhD. University of Alcalá 2011.

MEMBERSHIPS

  • Member: RNA Institute, University of Pennsylvania
  • Member: Institute for translational medicine and therapeutics (ITMAT), University of Pennsylvania
  • Member: Center for Targeted Therapeutics and Translational nanomedicine (CT3N), University of Pennsylvania
  • Member of the Cardiovascular Institute of the University of Pennsylvania
  • Member of the “American Heart Association”
  • Member of “North America Society of Thrombosis and Hemostasis”
  • Member of “American Society of Gene and Cell Therapy“

HONORS & AWARDS

  • NIH: R01. Targeting the gatekeepers: Bolstering blood-brain barrier function using targeted nanomedicine in acute ischemic stroke. Role: Principal Investigator. 5th percentile impact score: 27.
  • NIH: STTR. Next-generation nanomedicine for acute ischemic stroke (>$650k). NanoMuse
  • CT3N Pilot grant: Red blood cells as carriers of prohemostatic drugs ($40K). Principal investigator.
  • Dream Team (CVI-0.5MM): “Nanomedicine for Stroke”. Co-Investigator
  • American Heart Association Career Development Award ($231k): “Cell specific targeted drug delivery to the inflamed brain” American Heart Association. Principal investigator
  • 1 Million Dollar Ride grant ($35k): “Enhancing coagulation factor VIIa expression in skeletal muscle: application to hemophilia gene therapy”. Principal investigator
  • Spanish Ministry Health: predoctoral fellowship
  • Mapfre predoctoral grant (Spain, $15k)
  • Best of Molecular Therapy Award. To the publication: “Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke.”
  • Patent application: “Compositions and methods for reducing nanoparticle-associated coagulation”
  • Inventors: Brenner JS, Omo-Lamai S, Zamora ME, Muzykantov VR, Marcos-Contreras OA, Myerson JW
  • Patent application: “Targeted Delivery of Therapeutic Agents to the Central Nervous System and Methods of Use for Treatment of Neurological Conditions”
  • Inventors: Marcos-Contreras OA, Glassman P, Nong J, Brenner JS, and Muzykantov VR
  • Patent application: “Targeted Therapeutic Lipid Nanoparticles and Methods of Use”
  • Inventors: Marcos-Contreras OA, Glassman P, Nong J, Brenner JS, Weissman D and Muzykantov VR
  • Patent application: “ Therapeutic Targeting of Lipid Nanoparticles”
  • Inventors: Shuvaev V, Parhiz H, Marcos-Contreras OA, Weissman D and Muzykantov VR
  • American Heart Association Career Development Award
  • Young Investigator Award. The International Society of Thrombosis and Haemostasis (ISTH)
  • Young Investigator Award. The International Society of Thrombosis and Haemostasis (ISTH)

PUBLICATIONS

  1. Targeted lipid nanoparticles containing IL-10 mRNA improve outcomes in experimental intracerebral hemorrhage.
    Reyes-Esteves S, Majumder A, Marzolini N, Zamora M, Wang Y, Espy C, Papp TE, Akyianu A, Nong J, Messe L, Omo-Lamai S, Parhiz H, Myerson J, Marcos-Contreras O, Brenner J.Res Sq [Preprint]. 2025 Apr 8:rs.3.rs-6347773. doi: 10.21203/rs.3.rs-6347773/v1.PMID: 40297702 Free PMC article. Preprint.
  2. Biomechanical and Functional Features of the Carrier Erythrocytes Prolonging Circulation Time of Biotherapeutic Targeted to Glycophorin A.
    Peshkova AD, Brysgel TV, Mody P, Nong J, Wang Z, Myerson JW, Litvinov RI, Weisel JW, Brenner JS, Glassman PM, Marcos-Contreras OA, Muzykantov VR.Bioconjug Chem. 2025 Feb 19;36(2):263-275. doi: 10.1021/acs.bioconjchem.4c00522. Epub 2025 Jan 27.PMID: 39869932
  3. Multi-stage-mixing to control the supramolecular structure of lipid nanoparticles, thereby creating a core-then-shell arrangement that improves performance by orders of magnitude.
    Nong J, Gong X, Dang QM, Tiwari S, Patel M, Wu J, Hanna A, Park WJ, Atochina-Vasserman EN, Huang HT, Marcos-Contreras OA, Morris-Blanco KC, Miner JJ, Weissman D, Muzykantov VR, Gupta K, Issadore D, Myerson JW, Wang Z, Brenner JS. bioRxiv [Preprint]. 2025 Feb 11:2024.11.12.623321. doi: 10.1101/2024.11.12.623321PMID: 39605450 Free PMC article. Preprint.
  4. A percolation-type criticality threshold controls immune protein coating of surfaces.
    Wang Z, Kulkarni S, Nong J, Zamora M, Ebrahimimojarad A, Hood E, Shuvaeva T, Zaleski M, Gullipalli D, Wolfe E, Espy C, Arguiri E, Wang Y, Marcos-Contreras OA, Song W, Muzykantov VR, Fu J, Radhakrishnan R, Myerson JW, Brenner JS. bioRxiv [Preprint]. 2024 Oct 18:2024.10.15.618530. doi: 10.1101/2024.10.15.618530. PMID: 39464129 Free PMC article. Preprint.
  5. Marginated Neutrophils in the Lungs Effectively Compete for Nanoparticles Targeted to the Endothelium, Serving as a Part of the Reticuloendothelial System.
    Zamora ME, Essien EO, Bhamidipati K, Murthy A, Liu J, Kim H, Patel MN, Nong J, Wang Z, Espy C, Chaudhry FN, Ferguson LT, Tiwari S, Hood ED, Marcos-Contreras OA, Omo-Lamai S, Shuvaeva T, Arguiri E, Wu J, Rauova L, Poncz M, Basil MC, Cantu E, Planer JD, Spiller K, Zepp J, Muzykantov VR, Myerson JW, Brenner JS. ACS Nano. 2024 Aug 20;18(33):22275-22297. doi: 10.1021/acsnano.4c06286. Epub 2024 Aug 6. PMID: 39105696 Free PMC article.
  6. Nanocarriers' repartitioning of drugs between blood subcompartments as a mechanism of improving pharmacokinetics, safety, and efficacy.
    Zaleski MH, Omo-Lamai S, Nong J, Chase LS, Myerson JW, Glassman PM, Lee F, Reyes-Esteves S, Wang Z, Patel MN, Peshkova AD, Komatsu H, Axelsen PH, Muzykantov VR, Marcos-Contreras OA, Brenner JS. J Control Release. 2024 Oct;374:425-440. doi: 10.1016/j.jconrel.2024.07.070. Epub 2024 Aug 26. PMID: 39103056
  7. Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury.
    Omo-Lamai S, Nong J, Savalia K, Kelley BJ, Wu J, Esteves-Reyes S, Chase LS, Muzykantov VR, Marcos-Contreras OA, Dollé JP, Smith DH, Brenner JS. PLoS One. 2024 Jun 10;19(6):e0297451. doi: 10.1371/journal.pone.0297451. eCollection 2024. PMID: 38857220 Free PMC article.
    Differential Impact In Vivo of Pf4-ΔCre-Mediated and Gp1ba-ΔCre-Mediated Depletion of Cyclooxygenase-1 in Platelets in Mice.
    Tang SY, Lordan R, Meng H, Auerbach BJ, Hennessy EJ, Sengupta A, Das US, Joshi R, Marcos-Contreras OA, McConnell R, Grant GR, Ricciotti E, Muzykantov VR, Grosser T, Weiljie AM, FitzGerald GA. Arterioscler Thromb Vasc Biol. 2024 Jun;44(6):1393-1406. doi: 10.1161/ATVBAHA.123.320295. Epub 2024 Apr 25. PMID: 38660804 Free PMC article.
  8. Lipid Nanoparticle-Associated Inflammation is Triggered by Sensing of Endosomal Damage: Engineering Endosomal Escape Without Side Effects.
    Omo-Lamai S, Wang Y, Patel MN, Essien EO, Shen M, Majumdar A, Espy C, Wu J, Channer B, Tobin M, Murali S, Papp TE, Maheshwari R, Wang L, Chase LS, Zamora ME, Arral ML, Marcos-Contreras OA, Myerson JW, Hunter CA, Tsourkas A, Muzykantov V, Brodsky I, Shin S, Whitehead KA, Gaskill P, Discher D, Parhiz H, Brenner JS. bioRxiv [Preprint]. 2024 Apr 18:2024.04.16.589801. doi: 10.1101/2024.04.16.589801. PMID: 38659905 Free PMC article. Preprint.
  9. Combination of Physicochemical Tropism and Affinity Moiety Targeting of Lipid Nanoparticles Enhances Organ Targeting.
    Zamora ME, Omo-Lamai S, Patel MN, Wu J, Arguiri E, Muzykantov VR, Myerson JW, Marcos-Contreras OA, Brenner JS. Nano Lett. 2024 Apr 10:10.1021/acs.nanolett.3c05031. doi: 10.1021/acs.nanolett.3c05031. Online ahead of print. PMID: 38598417
  10. Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke.
    Nong J, Glassman PM, Shuvaev VV, Reyes-Esteves S, Descamps HC, Kiseleva RY, Papp TE, Alameh MG, Tam YK, Mui BL, Omo-Lamai S, Zamora ME, Shuvaeva T, Arguiri E, Gong X, Brysgel TV, Tan AW, Woolfork AG, Weljie A, Thaiss CA, Myerson JW, Weissman D, Kasner SE, Parhiz H, Muzykantov VR, Brenner JS, Marcos-Contreras OA. Mol Ther. 2024 May 1;32(5):1344-1358. doi: 10.1016/j.ymthe.2024.03.004. Epub 2024 Mar 7. PMID: 38454606 Free PMC article.
  11. Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and Solutions.
    Omo-Lamai S, Zamora ME, Patel MN, Wu J, Nong J, Wang Z, Peshkova A, Majumder A, Melamed JR, Chase LS, Essien EO, Weissman D, Muzykantov VR, Marcos-Contreras OA, Myerson JW, Brenner JS. Adv Mater. 2024 Jun;36(26):e2312026. doi: 10.1002/adma.202312026. Epub 2024 Mar 13. PMID: 38394670 Free PMC article
  12. Effective Prevention of Arterial Thrombosis with Albumin-Thrombin Inhibitor Conjugates.
    Marcos-Contreras OA, Myerson JW, Nong J, Brenner JS, Muzykantov VR, Glassman PM. Mol Pharm. 2023 Nov 6;20(11):5476-5485. doi: 10.1021/acs.molpharmaceut.3c00325. Epub 2023 Oct 12. PMID: 37823223 Free PMC article.
  13. Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and Solutions.
    Omo-Lamai S, Zamora ME, Patel MN, Wu J, Nong J, Wang Z, Peshkova A, Chase LS, Essien EO, Muzykantov V, Marcos-Contreras O, Myerson JW, Brenner JS. bioRxiv [Preprint]. 2023 Jul 25:2023.07.21.550080. doi: 10.1101/2023.07.21.550080. Update in: Adv Mater. 2024 Jun;36(26):e2312026. doi: 10.1002/adma.202312026. PMID: 37546837 Free PMC article. Preprint.
  14. Targeted Nanocarriers Co-Opting Pulmonary Intravascular Leukocytes for Drug Delivery to the Injured Brain. Nong J, Glassman PM, Myerson JW, Zuluaga-Ramirez V, Rodriguez-Garcia A, Mukalel A, Omo-Lamai S, Walsh LR, Zamora ME, Gong X, Wang Z, Bhamidipati K, Kiseleva RY, Villa CH, Greineder CF, Kasner SE, Weissman D, Mitchell MJ, Muro S, Persidsky Y, Brenner JS, Muzykantov VR, Marcos-Contreras OA. ACS Nano. 2023 Jul 25;17(14):13121-13136. doi: 10.1021/acsnano.2c08275. Epub 2023 Jul 11. PMID: 37432926 Free PMC article.
  15. Targeting lipid nanoparticles to the blood brain barrier to ameliorate acute ischemic stroke.
    Nong J, Glassman PM, Reyes-Esteves S, Descamps HC, Shuvaev VV, Kiseleva RY, Papp TE, Alameh MG, Tam YK, Mui BL, Omo-Lamai S, Zamora ME, Shuvaeva T, Arguiri E, Thaiss CA, Myerson JW, Weissman D, Kasner SE, Parhiz H, Muzykantov VR, Brenner JS, Marcos-Contreras OA. bioRxiv [Preprint]. 2023 Jun 13:2023.06.12.544645. doi: 10.1101/2023.06.12.544645. Update in: Mol Ther. 2024 May 1;32(5):1344-1358. doi: 10.1016/j.ymthe.2024.03.004. PMID: 37398465 Free PMC article. Preprint.
  16. Targeted drug delivery to the brain endothelium dominates over passive delivery via vascular leak in experimental intracerebral hemorrhage. Reyes-Esteves S, Nong J, Glassman PM, Omo-Lamai S, Ohashi S, Myerson JW, Zamora ME, Ma X, Kasner SE, Sansing L, Muzykantov VR, Marcos-Contreras OA, Brenner JS. J Control Release. 2023 Apr;356:185-195. doi: 10.1016/j.jconrel.2023.02.037. Epub 2023 Mar 7. PMID: 36868517 Free PMC article.
  17. Targeted In Vivo Loading of Red Blood Cells Markedly Prolongs Nanocarrier Circulation.
    Glassman PM, Villa CH, Marcos-Contreras OA, Hood ED, Walsh LR, Greineder CF, Myerson JW, Shuvaeva T, Puentes L, Brenner JS, Siegel DL, Muzykantov VR. Bioconjug Chem. 2022 Jul 20;33(7):1286-1294. doi: 10.1021/acs.bioconjchem.2c00196. Epub 2022 Jun 16. PMID: 35710322
  18. Dual Affinity to RBCs and Target Cells (DART) Enhances Both Organ- and Cell Type-Targeting of Intravascular Nanocarriers.
    Ferguson LT, Hood ED, Shuvaeva T, Shuvaev VV, Basil MC, Wang Z, Nong J, Ma X, Wu J, Myerson JW, Marcos-Contreras OA, Katzen J, Carl JM, Morrisey EE, Cantu E, Villa CH, Mitragotri S, Muzykantov VR, Brenner JS. ACS Nano. 2022 Mar 22;16(3):4666-4683. doi: 10.1021/acsnano.1c11374. Epub 2022 Mar 10. PMID: 35266686 Free PMC article.
  19. Added to pre-existing inflammation, mRNA-lipid nanoparticles induce inflammation exacerbation (IE).
    Parhiz H, Brenner JS, Patel PN, Papp TE, Shahnawaz H, Li Q, Shi R, Zamora ME, Yadegari A, Marcos-Contreras OA, Natesan A, Pardi N, Shuvaev VV, Kiseleva R, Myerson JW, Uhler T, Riley RS, Han X, Mitchell MJ, Lam K, Heyes J, Weissman D, Muzykantov VR. J Control Release. 2022 Apr;344:50-61. doi: 10.1016/j.jconrel.2021.12.027. Epub 2021 Dec 23. PMID: 34953981 Free PMC article.
  20. Combating Complement's Deleterious Effects on Nanomedicine by Conjugating Complement Regulatory Proteins to Nanoparticles.
    Wang Z, Hood ED, Nong J, Ding J, Marcos-Contreras OA, Glassman PM, Rubey KM, Zaleski M, Espy CL, Gullipali D, Miwa T, Muzykantov VR, Song WC, Myerson JW, Brenner JS.
    Adv Mater. 2022 Feb;34(8):e2107070. doi: 10.1002/adma.202107070. Epub 2022 Jan 11. PMID: 34910334 Free PMC article.
  21. Supramolecular arrangement of protein in nanoparticle structures predicts nanoparticle tropism for neutrophils in acute lung inflammation.
    Myerson JW, Patel PN, Rubey KM, Zamora ME, Zaleski MH, Habibi N, Walsh LR, Lee YW, Luther DC, Ferguson LT, Marcos-Contreras OA, Glassman PM, Mazaleuskaya LL, Johnston I, Hood ED, Shuvaeva T, Wu J, Zhang HY, Gregory JV, Kiseleva RY, Nong J, Grosser T, Greineder CF, Mitragotri S, Worthen GS, Rotello VM, Lahann J, Muzykantov VR, Brenner JS. Nat Nanotechnol. 2022 Jan;17(1):86-97. doi: 10.1038/s41565-021-00997-y. Epub 2021 Nov 18. PMID: 34795440 Free PMC article.
  22. Monoclonal antibody 2C5 specifically targets neutrophil extracellular traps.
    Mendes LP, Rostamizadeh K, Gollomp K, Myerson JW, Marcos-Contreras OA, Zamora M, Luther E, Brenner JS, Filipczak N, Li X, Torchilin VP. MAbs. 2020 Jan-Dec;12(1):1850394. doi: 10.1080/19420862.2020.1850394. PMID: 33323006 Free PMC article.
  23. Bivalent engagement of endothelial surface antigens is critical to prolonged surface targeting and protein delivery in vivo.
    Kiseleva RY, Glassman PG, LeForte KM, Walsh LR, Villa CH, Shuvaev VV, Myerson JW, Aprelev PA, Marcos-Contreras OA, Muzykantov VR, Greineder CF. FASEB J. 2020 Sep;34(9):11577-11593. doi: 10.1096/fj.201902515RR. Epub 2020 Aug 1. PMID: 32738178 Free PMC article.
  24. Molecularly Engineered Nanobodies for Tunable Pharmacokinetics and Drug Delivery.
    Glassman PM, Walsh LR, Villa CH, Marcos-Contreras OA, Hood ED, Muzykantov VR, Greineder CF. Bioconjug Chem. 2020 Apr 15;31(4):1144-1155. doi: 10.1021/acs.bioconjchem.0c00003. Epub 2020 Mar 20. PMID: 32167754 Free PMC article.
  25. Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier.
    Marcos-Contreras OA, Greineder CF, Kiseleva RY, Parhiz H, Walsh LR, Zuluaga-Ramirez V, Myerson JW, Hood ED, Villa CH, Tombacz I, Pardi N, Seliga A, Mui BL, Tam YK, Glassman PM, Shuvaev VV, Nong J, Brenner JS, Khoshnejad M, Madden T, Weissmann D, Persidsky Y, Muzykantov VR. Proc Natl Acad Sci U S A. 2020 Feb 18;117(7):3405-3414. doi: 10.1073/pnas.1912012117. Epub 2020 Jan 31. PMID: 32005712 Free PMC article.
  26. Cross-linker-Modulated Nanogel Flexibility Correlates with Tunable Targeting to a Sterically Impeded Endothelial Marker.
    Myerson JW, McPherson O, DeFrates KG, Towslee JH, Marcos-Contreras OA, Shuvaev VV, Braender B, Composto RJ, Muzykantov VR, Eckmann DM. ACS Nano. 2019 Oct 22;13(10):11409-11421. doi: 10.1021/acsnano.9b04789. Epub 2019 Oct 10. PMID: 31600053 Free PMC article.
  27. Combining vascular targeting and the local first pass provides 100-fold higher uptake of ICAM-1-targeted vs untargeted nanocarriers in the inflamed brain.
    Marcos-Contreras OA, Brenner JS, Kiseleva RY, Zuluaga-Ramirez V, Greineder CF, Villa CH, Hood ED, Myerson JW, Muro S, Persidsky Y, Muzykantov VR. J Control Release. 2019 May 10;301:54-61. doi: 10.1016/j.jconrel.2019.03.008. Epub 2019 Mar 11. PMID: 30871995 Free PMC article.
  28. Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.
    Zintner SM, Small JC, Pavani G, Dankner L, Marcos-Contreras OA, Gimotty PA, Kjelgaard-Hansen M, Wiinberg B, Margaritis P. Blood Adv. 2019 Feb 12;3(3):301-311. doi: 10.1182/bloodadvances.2018027219. PMID: 30705032 Free PMC article.
  29. Red blood cell-hitchhiking boosts delivery of nanocarriers to chosen organs by orders of magnitude.
    Brenner JS, Pan DC, Myerson JW, Marcos-Contreras OA, Villa CH, Patel P, Hekierski H, Chatterjee S, Tao JQ, Parhiz H, Bhamidipati K, Uhler TG, Hood ED, Kiseleva RY, Shuvaev VS, Shuvaeva T, Khoshnejad M, Johnston I, Gregory JV, Lahann J, Wang T, Cantu E, Armstead WM, Mitragotri S, Muzykantov V. Nat Commun. 2018 Jul 11;9(1):2684. doi: 10.1038/s41467-018-05079-7. PMID: 29992966 Free PMC article.
  30. Flexible Nanoparticles Reach Sterically Obscured Endothelial Targets Inaccessible to Rigid Nanoparticles.
    Myerson JW, Braender B, Mcpherson O, Glassman PM, Kiseleva RY, Shuvaev VV, Marcos-Contreras O, Grady ME, Lee HS, Greineder CF, Stan RV, Composto RJ, Eckmann DM, Muzykantov VR. Adv Mater. 2018 Aug;30(32):e1802373. doi: 10.1002/adma.201802373. Epub 2018 Jun 28. PMID: 29956381 Free PMC article.
  31. Molecular engineering of antibodies for site-specific covalent conjugation using CRISPR/Cas9.
    Khoshnejad M, Brenner JS, Motley W, Parhiz H, Greineder CF, Villa CH, Marcos-Contreras OA, Tsourkas A, Muzykantov VR. Sci Rep. 2018 Jan 29;8(1):1760. doi: 10.1038/s41598-018-19784-2. PMID: 29379029 Free PMC article.
  32. Vascular endothelial effects of collaborative binding to platelet/endothelial cell adhesion molecule-1 (PECAM-1).
    Kiseleva RY, Greineder CF, Villa CH, Marcos-Contreras OA, Hood ED, Shuvaev VV, DeLisser HM, Muzykantov VR. Sci Rep. 2018 Jan 24;8(1):1510. doi: 10.1038/s41598-018-20027-7. PMID: 29367646 Free PMC article.
  33. Hyperfibrinolysis increases blood-brain barrier permeability by a plasmin- and bradykinin-dependent mechanism.
    Marcos-Contreras OA, Martinez de Lizarrondo S, Bardou I, Orset C, Pruvost M, Anfray A, Frigout Y, Hommet Y, Lebouvier L, Montaner J, Vivien D, Gauberti M. Blood. 2016 Nov 17;128(20):2423-2434. doi: 10.1182/blood-2016-03-705384. Epub 2016 Aug 16. PMID: 27531677 Free article.
  34. Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.
    Marcos-Contreras OA, Smith SM, Bellinger DA, Raymer RA, Merricks E, Faella A, Pavani G, Zhou S, Nichols TC, High KA, Margaritis P. Blood. 2016 Feb 4;127(5):565-71. doi: 10.1182/blood-2015-09-671420. Epub 2015 Dec 23. PMID: 26702064 Free PMC article.
  35. The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.
    Pavani G, Ivanciu L, Faella A, Marcos-Contreras OA, Margaritis P. Blood. 2014 Aug 14;124(7):1157-65. doi: 10.1182/blood-2014-04-567297. Epub 2014 Jun 23. PMID: 24957146 Free PMC article.
  36. Ultra-sensitive molecular MRI of vascular cell adhesion molecule-1 reveals a dynamic inflammatory penumbra after strokes.
    Gauberti M, Montagne A, Marcos-Contreras OA, Le Béhot A, Maubert E, Vivien D. Stroke. 2013 Jul;44(7):1988-96. doi: 10.1161/STROKEAHA.111.000544. Epub 2013 Jun 6. PMID: 23743972
  37. Clot penetration and retention by plasminogen activators promote fibrinolysis.
    Marcos-Contreras OA, Ganguly K, Yamamoto A, Shlansky-Goldberg R, Cines DB, Muzykantov VR, Murciano JC. Biochem Pharmacol. 2013 Jan 15;85(2):216-22. doi: 10.1016/j.bcp.2012.10.011. Epub 2012 Oct 23. PMID: 23098998
  38. Sustained thromboprophylaxis mediated by an RBC-targeted pro-urokinase zymogen activated at the site of clot formation. Zaitsev S, Spitzer D, Murciano JC, Ding BS, Tliba S, Kowalska MA, Marcos-Contreras OA, Kuo A, Stepanova V, Atkinson JP, Poncz M, Cines DB, Muzykantov VR. Blood. 2010 Jun 24;115(25):5241-8. doi: 10.1182/blood-2010-01-261610. Epub 2010 Apr 21. PMID: 20410503 Free PMC article.